Last updated 2026-07-30
TL;DR
Oral dapsone overdose (often 1-15g) causes methemoglobinemia and hemolytic anemia, treated with methylene blue and sometimes exchange transfusion. Topical dapsone (Aczone) is absorbed minimally and almost never causes this. G6PD-deficient patients face much higher risk from oral dapsone, which is why screening matters before anyone starts the pill form.
What is dapsone overdose and toxicity, exactly?
Dapsone toxicity means the drug has overwhelmed the body's ability to process it safely, usually showing up as methemoglobinemia (blood that can't carry oxygen properly) and hemolytic anemia (red blood cells breaking apart faster than the body replaces them). This is almost entirely an oral dapsone story. Oral dapsone is a sulfone antibiotic used for leprosy (Hansen's disease), dermatitis herpetiformis, and Pneumocystis pneumonia prevention, among other things. Topical dapsone gel (Aczone 5% and 7.5%), FDA-approved for acne, is absorbed into the bloodstream at levels dramatically lower than an oral dose [1]. The confusion between these two forms is the single most dangerous misunderstanding a reader can walk away with. Oral dapsone toxicity is a real medical emergency reported in poison control literature and case series. Topical dapsone toxicity, by contrast, is rare enough that it barely shows up in the case report literature at all. If you're using Aczone on your face for acne, you are not in the same risk category as someone taking 100mg oral dapsone daily for dermatitis herpetiformis, and you're nowhere near the risk category of someone who has ingested a handful of dapsone tablets intentionally or by accident. One pharmacokinetic study found that a single 20mg dose of topical dapsone gel produced peak plasma concentrations about 1/100th of what a 100mg oral dose produces [2]. That ratio matters. It's why dermatologists prescribe topical dapsone to acne patients without requiring G6PD blood tests, while oral dapsone almost always requires that screening first.
How much oral dapsone does it take to cause an overdose?
Case reports describe serious toxicity starting around 1 to 2 grams ingested at once, with severe, sometimes fatal outcomes reported at doses in the 10 to 15 gram range [3]. For context, a typical therapeutic oral dose for dermatitis herpetiformis runs 50 to 300mg per day, and leprosy treatment regimens typically use 100mg daily [4]. So an overdose in the literature usually means someone took ten to over a hundred times a normal daily dose in one sitting, whether accidentally or intentionally. A case series published in the Journal of Medical Toxicology described patients presenting after ingesting between 1.5 and 15 grams of dapsone, with methemoglobin levels reaching as high as 50 to 60 percent of total hemoglobin in the more severe cases (normal is under 1 to 2 percent) [3]. Symptoms in these cases included cyanosis (bluish skin from poor oxygenation), shortness of breath, confusion, and in the worst cases, seizures or cardiac arrest. There is no validated "safe" overdose threshold below which nothing happens. Some people with normal G6PD enzyme levels tolerate higher exposures with milder symptoms; people with G6PD deficiency can have serious hemolysis at doses close to therapeutic range. That variability is exactly why screening exists before oral dapsone starts, not after.
What are the symptoms of dapsone toxicity?
The two hallmark problems are methemoglobinemia and hemolytic anemia, and they often show up together within hours of a large oral exposure. Methemoglobinemia symptoms include bluish or gray-colored skin and lips (cyanosis) that doesn't improve with supplemental oxygen, headache, fatigue, shortness of breath, rapid heart rate, and in severe cases, confusion, seizures, or loss of consciousness. The oxygen-carrying failure is the dangerous part. Pulse oximeters can give falsely reassuring readings in methemoglobinemia, which is why hospitals use co-oximetry blood testing to get an accurate number [5]. Hemolytic anemia symptoms include fatigue, pale or yellowish skin (jaundice), dark urine, rapid heartbeat, and abdominal or back pain as red blood cells break down. Dapsone's main metabolite, dapsone hydroxylamine, is the chemical directly responsible for oxidizing hemoglobin and damaging red blood cell membranes [6]. This hemolysis happens to some degree in nearly everyone on oral dapsone, even at normal doses, which is why routine blood monitoring is standard for anyone prescribed the oral form long-term. A separate and distinct danger is dapsone hypersensitivity syndrome, a delayed drug reaction that typically appears 2 to 6 weeks after starting oral dapsone. It causes fever, rash, and organ inflammation (commonly liver and lymph nodes) and carries a reported mortality rate in the range of 9 to 12 percent in some case series [7]. This is not an overdose phenomenon; it can happen at ordinary therapeutic doses and is a reason oral dapsone requires close medical supervision from day one.
Why does G6PD deficiency make oral dapsone so much more dangerous?
G6PD (glucose-6-phosphate dehydrogenase) is an enzyme red blood cells need to protect themselves from oxidative stress. People with G6PD deficiency, an inherited condition affecting an estimated 400 million people worldwide and roughly 1 in 10 African American men in the US, have red blood cells that are far more vulnerable to oxidizing drugs like dapsone [8]. When someone with G6PD deficiency takes oral dapsone, hemolysis can be sudden and severe, sometimes requiring transfusion. The FDA-approved prescribing information for oral dapsone explicitly states that patients should be tested for G6PD deficiency before starting therapy, and that hemolysis is dose-related and more pronounced in G6PD-deficient patients [9]. This is the single most important safety step before anyone starts oral dapsone. It is a simple blood test, and it is not optional in responsible prescribing. If you've been offered oral dapsone without a G6PD conversation, ask about it directly before you take the first pill. Topical dapsone carries a much smaller version of this same theoretical risk because of its low systemic absorption. The Aczone label does not require G6PD testing before use, and manufacturer-sponsored studies in G6PD-deficient patients using topical dapsone found no clinically meaningful hemolysis signal [1]. That said, some clinicians still exercise caution in patients with known severe G6PD deficiency, especially with the higher-strength 7.5% formulation used over large body surface areas.
Can topical dapsone (Aczone) cause an overdose or systemic toxicity?
Practically speaking, no, not in the way oral dapsone can. Topical dapsone gel is applied to the face (or sometimes chest and back) in small amounts, and its systemic absorption is low enough that clinically meaningful methemoglobinemia or hemolysis from normal use is rare in the published literature [1] [2]. That doesn't mean topical dapsone has zero systemic exposure. Detectable blood levels do occur, which is exactly why the absorption studies were done in the first place. But the levels seen with the approved dosing regimen (a thin layer once or twice daily) sit far below the range where toxicity symptoms have been reported with the oral drug. The realistic risks with topical dapsone are local, not systemic: dryness, peeling, redness at the application site, and a well-known but generally harmless interaction where using benzoyl peroxide at the same time as topical dapsone can cause temporary yellow-orange skin discoloration [1]. That's a cosmetic nuisance, not a toxicity concern. If you're trying to figure out whether topical dapsone is actually working for your skin, or how it compares to other acne treatments, that's a separate evidence question from the toxicity one, and it's worth reading up on the dapsone success rate and dapsone before and after data separately from anything about oral drug safety.
How is dapsone overdose or toxicity treated?
Treatment depends on how severe the methemoglobinemia and hemolysis are, and it happens in a hospital, not at home. Methylene blue is the standard first-line treatment for symptomatic methemoglobinemia, typically given intravenously, and it works by helping the body convert methemoglobin back to normal, oxygen-carrying hemoglobin [5]. It usually works within 30 to 60 minutes in patients with adequate G6PD enzyme function. Here's the catch: methylene blue itself can trigger severe hemolysis in G6PD-deficient patients, so clinicians have to weigh that risk carefully, sometimes opting for lower doses or alternative treatments like cimetidine (which can reduce formation of the toxic dapsone metabolite) in patients known or suspected to be G6PD deficient [6]. Activated charcoal, sometimes given in repeated doses, can help reduce further absorption if given early after a large ingestion, since dapsone undergoes enterohepatic recirculation [3]. In the most severe cases, with very high methemoglobin levels or ongoing hemolysis that isn't responding to first-line treatment, exchange transfusion has been used to physically remove the toxic metabolites and damaged red blood cells from circulation. Anyone who has taken (or given a child) an unknown or large amount of dapsone should call Poison Control at 1-800-222-1222 or go to an emergency room immediately, rather than waiting to see if symptoms appear. Symptoms can take hours to peak.
What are the long-term risks of taking oral dapsone regularly?
Beyond acute overdose, people on long-term oral dapsone therapy (for conditions like dermatitis herpetiformis or leprosy) face ongoing, dose-independent risks that require monitoring for as long as they're on the drug. Agranulocytosis, a dangerous drop in infection-fighting white blood cells, is a recognized but uncommon risk of oral dapsone, typically emerging in the first few months of therapy [4] [7]. It's why prescribers order regular complete blood counts, often weekly for the first month, then tapering to monthly or less frequent as therapy continues without problems. Peripheral neuropathy (numbness, tingling, or weakness, usually in the hands and feet) is another long-term risk associated with prolonged oral dapsone use, and it's not always fully reversible after stopping the drug [4]. Liver toxicity and the dapsone hypersensitivity syndrome mentioned earlier are additional reasons oral dapsone requires ongoing clinical follow-up rather than a one-time prescription. None of this applies in the same way to short courses of topical dapsone for acne. That's a genuinely different risk profile, and conflating the two is where a lot of the online confusion about "dapsone risk" comes from.
How common is dapsone overdose in real-world poison control data?
Dapsone overdose is not common compared to, say, acetaminophen or opioid overdoses, but it does show up consistently in toxicology case literature, generally from intentional overdose, accidental ingestion by children, or dosing errors in patients on chronic oral therapy [3]. Most published case series describing severe dapsone toxicity come from single-patient or small-cohort reports rather than large national surveillance datasets, which makes exact incidence numbers hard to pin down. What is consistent across the literature is the pattern: methemoglobin levels climbing over 6 to 24 hours after ingestion, sometimes requiring repeat doses of methylene blue because dapsone's long half-life (about 20 to 30 hours) and active metabolite keep re-triggering oxidative stress even after initial treatment [3] [6]. This prolonged course is one of the more distinctive and dangerous features of dapsone overdose compared to some other oxidizing drugs: a single dose of methylene blue often isn't enough, and patients can need close monitoring in an ICU setting for a day or more.
Table: oral vs topical dapsone risk comparison
| Factor | Oral dapsone | Topical dapsone (Aczone) | |
|---|---|---|---|
| FDA-approved use | Dermatitis herpetiformis, leprosy, PCP prophylaxis [4] [9] | Acne vulgaris, ages 9+ (5%) and 12+ (7.5%) [1] | |
| Typical dose | 50-300mg/day [4] | Thin layer to face once daily | |
| G6PD testing required before use | Yes, per FDA label [9] | Not required per label [1] | |
| Systemic absorption | High, full first-pass | Very low, roughly 1/100th of oral peak levels [2] | |
| Methemoglobinemia risk | Established, dose-related [5] [6] | Rare, not established as clinically significant [1] | |
| Hemolytic anemia risk | Established, especially in G6PD deficiency [9] | Not established as clinically significant [1] | |
| Dapsone hypersensitivity syndrome | Reported, 9-12% mortality in case series [7] | Not reported | |
| Routine blood monitoring | Yes, CBC monitoring recommended [4] | Not routinely required | This table is the shortest way to see why the same drug name carries two very different risk conversations depending on the route. |
Who should never take oral dapsone, or should only take it with extra caution?
People with known G6PD deficiency are the clearest group needing extreme caution or avoidance, since oral dapsone's hemolytic effect is directly tied to that enzyme's function [9]. Anyone with a personal or family history of unexplained anemia after taking sulfa drugs, fava beans, or certain other medications should raise that with a prescriber before starting oral dapsone, since it can be an unrecognized sign of G6PD deficiency. People with pre-existing anemia, significant liver disease, or a history of methemoglobinemia from any cause also warrant extra caution and closer monitoring on oral dapsone. Pregnant patients need individualized risk discussion with their prescriber, since dapsone crosses the placenta and neonatal hemolysis and methemoglobinemia have been reported [4]. None of this is a reason to panic if you're using topical Aczone for acne under normal dermatologic supervision. It's a reason to be precise about which drug and which route you're actually talking about when you read about dapsone risk online. If you're weighing whether topical dapsone fits your acne treatment plan at all, the dapsone pros and cons and is dapsone worth it pages cover that decision without wading into oral drug safety data that doesn't apply to your situation.
What should you do if you're prescribed oral dapsone or considering topical dapsone?
If a prescriber offers you oral dapsone, ask directly whether you've had a G6PD test, and if not, ask for one before starting. This is standard of care, not an extra precaution, per the FDA label [9]. Ask what blood monitoring schedule they plan to use, since regular CBCs catch agranulocytosis and hemolysis early, before they become emergencies. If you're considering topical dapsone (Aczone) for acne, the conversation is much simpler: it's an FDA-approved topical, G6PD testing isn't routinely required, and the main things to watch for are local skin irritation and the benzoyl peroxide discoloration interaction, not systemic blood toxicity [1]. Getting it through a provider-reviewed telehealth pathway, like the one Dapsone Rx connects patients through with its fulfilling pharmacy partners, still means a licensed clinician reviews your history before you get a prescription, even though the topical form doesn't carry the same lab-testing burden as the oral drug. If you want to see what results look like before committing, the dapsone results timeline and dapsone reviews pages are a reasonable next stop, since toxicity risk is only half the decision; efficacy and timeline are the other half.
Frequently asked questions
What is the lethal dose of dapsone?
Case reports describe severe, sometimes fatal toxicity at doses in the 10 to 15 gram range, though outcomes vary based on individual factors like G6PD status and how quickly treatment starts [3]. There's no single universally agreed lethal dose; smaller ingestions (1-2g) have caused serious methemoglobinemia in some patients, especially without prompt treatment.
Is topical dapsone (Aczone) safe if I have G6PD deficiency?
The Aczone label doesn't require G6PD testing before use, and studies in G6PD-deficient patients using topical dapsone found no clinically meaningful hemolysis [1]. Some clinicians still exercise added caution with the 7.5% strength over large areas. Tell your prescriber about known G6PD deficiency regardless, so it's documented.
What are the first signs of dapsone toxicity?
Early signs include bluish or grayish skin color (cyanosis) that doesn't improve with oxygen, fatigue, headache, and shortness of breath from methemoglobinemia, sometimes alongside dark urine and jaundice from hemolysis [5][6]. Symptoms can take several hours to peak after a large oral ingestion, so early presentation can look milder than it becomes.
Does topical dapsone show up on a G6PD or blood test?
Topical dapsone can produce low, detectable blood levels of the drug, but the approved dosing regimen hasn't been shown to cause clinically meaningful methemoglobinemia or hemolysis, so routine blood testing isn't required by the FDA label [1][2]. If you have known severe G6PD deficiency, mention it to your prescriber anyway.
How is dapsone overdose treated in the hospital?
Methylene blue IV is the standard treatment for symptomatic methemoglobinemia, usually working within 30-60 minutes, though it must be used cautiously in G6PD-deficient patients since it can itself trigger hemolysis [5][6]. Activated charcoal and, in severe cases, exchange transfusion are also used depending on severity and timing.
Can you overdose on Aczone (topical dapsone gel)?
Clinically meaningful systemic overdose from topical Aczone used as directed is not established in the published literature, given its very low systemic absorption compared to oral dapsone [1][2]. Swallowing a tube of gel or using it far outside labeled directions would be a different situation and warrants a call to Poison Control (1-800-222-1222).
What is dapsone hypersensitivity syndrome?
It's a delayed, serious drug reaction to oral dapsone that typically appears 2 to 6 weeks after starting therapy, causing fever, rash, and inflammation of organs like the liver and lymph nodes. Case series report mortality around 9 to 12 percent [7]. It's a reason oral dapsone patients need close monitoring in the first months of treatment, and it hasn't been established as a risk with topical dapsone.
Why do you need a G6PD test before taking oral dapsone?
G6PD deficiency, an inherited enzyme deficiency affecting roughly 1 in 10 African American men in the US and about 400 million people worldwide, makes red blood cells far more vulnerable to the oxidative damage oral dapsone causes [8]. The FDA label recommends G6PD testing before starting oral dapsone because hemolysis is more severe and can be dangerous in deficient patients [9].
What's the difference between dapsone for acne and dapsone for leprosy?
Dapsone for acne is a topical gel (Aczone 5%/7.5%) applied to skin with low systemic absorption. Dapsone for leprosy is an oral tablet, typically 100mg daily, fully absorbed and requiring G6PD testing and blood monitoring [4][9]. Same drug name, very different risk profile based on route and dose.
Can children overdose on dapsone?
Yes, accidental pediatric ingestion of oral dapsone tablets is a recognized cause of severe methemoglobinemia in case reports, and children may be more vulnerable due to lower body weight relative to dose [3]. If a child ingests any oral dapsone, call Poison Control (1-800-222-1222) or go to an ER immediately rather than waiting for symptoms.
How long does dapsone toxicity last?
Because dapsone has a long half-life (roughly 20-30 hours) and an active metabolite that keeps causing oxidative stress, methemoglobinemia and hemolysis from a significant oral overdose can persist or recur over a day or more, sometimes requiring repeat methylene blue doses and ICU monitoring [3][6].
Does alcohol or other drugs make dapsone toxicity worse?
Other oxidizing drugs (some antimalarials, certain antibiotics, nitrites) can compound dapsone's methemoglobinemia risk, and drugs that inhibit dapsone metabolism can raise blood levels of its toxic metabolite [4][6]. Always give a prescriber a full medication list before starting oral dapsone; this isn't something to guess about.
Sources
- FDA, Aczone (dapsone) gel prescribing information: Topical dapsone gel absorption, G6PD testing not required, benzoyl peroxide interaction
- Piette et al., pharmacokinetic study of topical dapsone gel: Topical dapsone produces plasma concentrations far below oral dosing
- Ashurst et al., Journal of Medical Toxicology, dapsone overdose case series: Overdose ingestion amounts and methemoglobin levels in reported cases
- NORD, Dermatitis Herpetiformis and dapsone dosing information: Typical oral dapsone dosing ranges and long-term risks
- NIH, StatPearls, Methemoglobinemia: Methylene blue treatment mechanism and co-oximetry testing for methemoglobinemia
- NIH, StatPearls, Dapsone Toxicity: Dapsone hydroxylamine metabolite mechanism and hemolysis pathway
- Lorenz et al., dapsone hypersensitivity syndrome review: Dapsone hypersensitivity syndrome timing and mortality rate
- CDC, G6PD Deficiency fact sheet: G6PD deficiency prevalence in the US and worldwide
- FDA, oral dapsone tablets prescribing information: FDA recommendation for G6PD testing before oral dapsone and dose-related hemolysis